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INTRODUCTION
Fatigue is very common in many rheumatic diseases, in-
cluding rheumatoid arthritis (RA), and is reported by pa-
tients as one of the most important outcomes of the disease
(Hewlett et al., 2005). Fatigue that is present in RA is ex-
perienced differently, as viewed by patients, from ‘normal’
tiredness to overwhelming, uncontrollable, and, often, un-
treatable (Katz, 2017). Although fatigue is not clearly de-
fined, fatigue affects at least three-quarters of RA patients
(Wolfe et al., 1996; Pollard et al., 2006). Using a fatigue
Visual Analogue Scale, 50% of RA patients have fatigue,
which is at least five out of 10 (Hewlett et al., 2005) and
40% have severe fatigue (Andersson et al., 2013).
The importance of fatigue in RA is underlined by the find-
ing that more severe fatigue is predictive for decreased
mental and physical health-related quality of life, loss of
work ability and depression (Breedveld et al., 2005; La-
caille et al., 2007; Wolfe et al., 2009). Both a Patient Per-
spective Workshop at OMERACT (Outcome Measures in
Rheumatology) in 2007 and a EULAR/ACR task force in
2008 recommended that “each trial should report on fa-
tigue” (Kirwan et al., 2007; Aletaha et al., 2008).
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Patients with rheumatoid arthritis (RA) typically have many permanently inflamed joints. The in-
flammation inside the body can lead to general physical weakness, exhaustion, and drowsiness.
This feeling of extreme tiredness is also called “fatigue”. Some people find this to be the worst
symptom of the disease. However, the clinical significance of fatigue and its pathogenesis have
not been recognised. This study aimed to determine the development of fatigue depending on ac-
tivity and aggressiveness of RA. To achieve the goal, patients were interviewed and indicators of
disease activity and aggressiveness were determined: rheumatoid factor (RF), anti-cyclic citrulli-
nated peptide antibodies (anti-CCP), erythrocyte sedimentation rate (ESR), C reactive protein
(CRP), immunoglobulins IgA RF, IgM RF, IgG RF and anti-carbamylated protein antibodies (anti-
CarP). Based on the results of the survey, RA patients were divided into two groups — with and
without fatigue. In the group of RA patients with fatigue, statistically more often an increase in IgA
RF, IgM RF, and IgG RF levels was observed in those with elevated RF level, higher IgM RF and
IgG RF levels were associated with increase in IgA RF level, and increase in the IgG RF and
anti-CarP levels with elevation in the IgM RF level. A higher IgG RF level contributed to a higher
anti-CarP level increase. Significant differences in the levels of clinical and laboratory inflamma-
tory markers were not observed between the RA patients with and without fatigue. The obtained
data suggest that the aggressive course of RA, more than inflammation, may contribute to the de-
velopment of fatigue in RA patients.
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The cause of fatigue in RA is thought to be multifactorial. A
conceptual model suggests that fatigue is the result of inter-
actions between several factors: behavioural factors (feel-
ings, thoughts, behaviours) and disease-process related fac-
tors, cognitive and personal factors (personal life issues)
(Hewlett et al., 2011). Scientific data supporting this model
are mostly derived from cross-sectional studies and are con-
flicting. Fatigue tends to correlate with disease activity, but
often the association is weak (Bergman et al., 2009; Van
Hoogmoed et al., 2010; Nikolaus et al., 2013; Madsen et
al., 2016). More strong correlation is with pain and physical
impairments (Pollard et al., 2006; Nikolaus et al., 2013).
When RA flare develops, usually pain and fatigue increase
(Barlett et al., 2012). Reports on fatigue in cases of RA are
not always consistent between studies. In one study, high
fatigue was associated with female gender, disease activity,
joint dysfunction, treatment and multimorbidity (especially
obesity and depression). However, severe fatigue in another
study was associated with RA patients’ self-rated poor
health, pain and anxiety/depression, but not physical func-
tion (Demmelmaier et al., 2018).
Fatigue is often present even if RA activity is low. This can
be due to common chronic pain in RA, which can lead to
poor sleep, depressed mood, and fatigue (Katz, 2017;
Bingham et al., 2019; Junghaenel et al., 2019; Primdahl et
al., 2019; Silva et al, 2019). Also, 10% of RA patients re-
port depression in early RA (Holdren et al., 2019). Residual
fatigue persists for many RA patients with a sustained state
of low disease activity (Strand et al., 2015). Approximately
15% of RA patients were not in fatigue remission when the
disease activity score (DAS) was in the remission stage
(DAS of < 2.6) (Druce et al., 2016). The presence of sicca
symptoms, greater severity of morning stiffness, and pres-
ence of psychological distress at baseline were associated
with baseline fatigue and persistent fatigue at five years,
and association between baseline fatigue or persistent fa-
tigue and the DAS28 (erythrocyte sedimentation reaction
(ESR)) (Rodríguez-Muguruza et al., 2020).
Previous studies have shown that a combined increase in
immunoglobulin IgM rheumatoid factor (RF) and IgA RF,
with or without IgG RF, is the most common RF pattern
found in RA patients. Several studies have shown that RA
patients with an increase in IgA RF develop a more severe
disease, with bone erosions or extra-articular manifesta-
tions, or both, than patients without IgA RF (Jonsson et al.,
1998).
Anti-carbamylated proteins antibodies (anti-CarP) have
been identified as a newer biomarker in RA, with a preva-
lence of 16–45% and a significant association with erosive
damage and radiographic progression (Shi et al., 2013; Shi
et al., 2014; van Delft et al., 2017; Truchetet et al., 2017).
From previous studies, it remains unclear whether RA pa-
tients suffer from higher levels of fatigue, and whether ex-
cessive fatigue is related to the disease. In addition, the role
of inflammation and autoantibodies produced in RA in rela-
tion to fatigue is unclear. Therefore, we identified a need to
carry out a study in RA patients, assessing the degree of in-
flammation by means of clinical and laboratory indices. We
used a validated fatigue questionnaire (Minnock et al.,
2017) to determine if RA patients' fatigue could be pre-
dicted by clinical and laboratory disease-related variables,
particularly inflammation and aggressiveness.
MATERIALS AND METHODS
Patients groups. This prospective cohort study included
patients from Rîga East Clinical University Hospital in the
period from February to May 2020. Patient inclusion crite-
ria were: primary or remotely diagnosed with RA, and age
over 18 years. All patients met the RA classification criteria
of the American College of Rheumatology and the Euro-
pean League Against Rheumatism in 2010 (Aletaha et al.,
2010). The exclusion criteria were: other rheumatic or in-
flammatory diseases, and age below 18. Respondents with
RA were divided into two groups according to whether they
had any kind of subjective fatigue, based on the answers of
a written questionnaire.
Thirty Caucasian RA patients were included in the study:
23 female (76.7%) and 7 male (23.3%). The average age
of the respondents was 59.5 ± 11.2 (ranging from 39 to 79).
From all responders, 20 patients reported fatigue, 16 of
them were female (80%) and 4 were male (20%), with the
average age 59.2 ± 10.7 (ranging from 39 to 75). Ten RA
patients without subjective symptoms of fatigue were in-
cluded in the control group — seven female (70%) and
three male (30%), with average age 60.2 ± 12.0 (ranging
from 45 to 79). In the RA group of patients with fatigue, the
mean pain score on the visual analogue scale (VAS) in cm
was 4.72 ± 2.16, morning stiffness (in hours) median was
IQR 1.75 (0.5–3.0) and the integrated parameter DAS28
(CRP) was 3.58 ± 1.15. However, in the RA group of pa-
tients without fatigue, the mean pain score on the visual an-
alogue scale (in cm) was 4.52 ± 2.16, morning stiffness (in
hours) was median IQR 1.00 (0.39–2.13) and the integrated
parameter DAS28 (CRP) as 3.58 ± 1.15.
The Ethics Committee of Rîga Stradiòð University ap-
proved the study protocol and all individuals participating
in this study provided informed consent before their inclu-
sion.
Sample collection and preparation. All clinical laboratory
indicators were determined in a respective clinic’s local lab-
oratory. Ethylene Diaminetetraacetic acid (EDTA) anti-co-
agulated peripheral blood samples were collected from RA
patients with and without fatigue. Plasma was separated
from peripheral blood by centrifugation. The following pa-
rameters were estimated in both groups: RF, anti-cyclic
citrullinated peptide antibodies (anti-CCP), erythrocyte sed-
imentation rate (ESR), C-reactive protein (CRP), immuno-
globulins IgA RF, IgG RF, IgM RF and anti-carbamylated
proteins antibodies (anti-CarP). CRP level higher than 8
mg/l, and ESR level greater than 30 mm/h were noted to
signify active disease. The Disease Activity Score 28
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(DAS28) was calculated using the CRP result. The follow-
ing DAS28 reference intervals were taken into account:
< 2.6 remission, > 2.6–3.2 low disease activity, > 3.2–5.1
moderate disease activity and > 5.1 high RA activity
(Jensen Hansen et al., 2017). Remission was observed in
13.3% of RA patients, low disease activity in 30.0% pa-
tients, moderately high in 43.3% and high disease activity
in 13.3% of RA patients. The laboratory results of RF and
anti-CCP were obtained to analyse the aggressiveness of
RA. A RF level  14 IU/ml and anti-CCP antibody level
 17 U/ml were evaluated as increased, taking into account
local laboratory reference intervals.
Detection of IgA RF, IgG RF, and IgM RF. IgA RF, IgG
RF and IgM RF levels were determined using a solid phase
enzyme immunoassay (ELISA) with highly purified Fc
fragment of human immunoglobulin IgG (IBL International
GMBH, Germany). The reaction was carried out according
to the manufacturer’s protocol.
In short, 100 µl of diluted plasma samples were added to the
corresponding wells as well as calibrators, positive and
negative controls. The microtitre plate was incubated for 30
minutes at 20–32°C and washed three times with 300 µl
washing buffer. 100 µl of conjugate was added into each
well, incubated for 30 minutes at 20–32°C and washed three
times with 300 µl washing buffer. After that, 100 µl of TMB
substrate was added to the wells, incubated for 30 minutes
at 20–32°C with the subsequent addition of 100 µl of stop
solution followed by incubation for at least five minutes.
The microtitre plate was agitated carefully for 5 seconds
and the optical density was measured spectrophotometri-
cally at a wavelength of 450 nm within the next 30 minutes.
Detection of anti-CarP. Anti-CarP antibodies were de-
tected using a Novateinbio ELISA kit (Novatein Biosci-
ences, USA) following the manufacturers protocol. 50 µl of
diluted standards, a sample diluent serving as a zero stan-
dard and samples were added to the corresponding micro-
titre plate wells. Subsequently, 100 µl of conjugate was
added to each well and mixed well. The plate was covered
and incubated for 1 hour at 37 °C. Then the microtitre plate
was washed five times by filling each well with the diluted
wash solution. 50 µl chromogen solution A and 50 µl
chromogen solution B was added to each well, the plate was
covered and incubated for 15 minutes at 37 °C. Then 50 µl
of stop solution was added to each well and mixed. The op-
tical density was measured spectrophotometrically at a
wavelength of 450 nm immediately after.
Statistical analysis. The Spearman rank correlation test
was used to measure the strength and direction of associa-
tion between variables in RA patients groups with and with-
out fatigue. The value of the Spearman’s correlation coeffi-
cient (rs) ranged from –1 to 1, with –1 being a very strong
negative correlation and 1 being a very strong positive cor-
relation. Statistical significance was set at p < 0.05.
All analyses and graphing were performed using Prism 8.01
for MacOS software (Graph Pad, San Diego, CA, USA).
RESULTS
RA patients without fatigue. In the RA patient group with-
out fatigue, the duration of morning stiffness, DAS28 and
CRP levels increased with increasing pain intensity (r = 0.7,
0.7, and 0.7, respectively), and with increasing duration of
morning stiffness, the level of DAS28 increased (r = 0.9;
Fig. 1). In contrast, increase in pain intensity was correlated
with a decrease of IgA RF (r = 0.5) and IgG RF (r = 0.6)
level. Increased morning stiffness, duration of pain and
DAS28 level were not significantly related to the level of
other parameters (Fig. 1).
Among the RA group patients without fatigue, in those with
increased RF level the IgM RF (r = 0.6) and anti-CCP (r =
0.6) level was significantly increased, but the level of other
parameters (ESR, CRP, IgA RF, IgG RF and anti-CarP) did
not change significantly (Figs. 1, 2).
In contrast, an increase in the anti-CCP level in the RA pa-
tient group without fatigue was correlated with increase in
IgA RF (r = 0.8) and IgM RF (r = 0.6) levels, but the levels
of other parameters (ESR, CRP, IgG RF and anti-CarP) did
not change significantly (Fig. 1).
In cases when increased levels of ESR was detected no sig-
nificant changes in the levels of IgA RF, IgM RF, IgG RF,
and anti-CarP were observed. However, and increase of
CRP was correlated with decrease of IgA RF (r = 0.8) and
IgG RF (r = 0.6) levels (Fig. 1).
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Fig. 1. Association strength between different variables measured: VAS
(mean pain score on the visual analogue scale), morning stiffness, DAS28
(disease activity score 28(, RF (rheumatoid factor), anti-CCP (anti-cyclic
citrullinated peptide antibodies), ESR (erythrocyte sedimentation rate),
CRP (C reactive protein), Ig (immunoglobulin)A RF, IgM RF, IgG RF and
CarP antibodies level) in RA patients without fatigue. Colour-filled circles
in matrix graph represent Spearman’s rank correlation coefficients (rs)
where size and color of the circles reflect the value of rs, and more intense
colour and bigger size corresponds to higher value of the coefficient (see
the scale on the right side).
In the group of RA patients without fatigue, increase in IgA
RF level was significantly correlated also IgG RF level in-
creased significantly (r = 0.7), but by increase in IgM RF
level the level of IgG RF (r = 0.6; Fig. 4) and anti-CarP (r =
0.7) level increased significantly (Figs. 1, 5).
The increase in IgG RF level did not affect the anti-CarP
level significantly (Figs. 1, 5).
RA patients with fatigue. In the RA group of patients with
fatigue, the level of DAS28 increased with increasing pain
intensity (r = 0.8) and duration of morning stiffness (r = 0.7;
Fig. 3). Increased morning stiffness was correlated with
pain intensity (r = 0.5) but was not significantly correlated
with other parameters (Fig. 3).
In the group of RA patients with fatigue, RF level was posi-
tively correlated with ESR (r = 0.5) and the IgA RF, IgM
RF, and IgG RF levels (r = 0.5, r = 0.9, and r = 0.7, respec-
tively). There was no significant relationship between RF
level and the levels of anti-CCP, CRP, and anti-CarP (Figs.
2, 3).
An increase in anti-CCP in RA patients with fatigue was re-
lated to a tendency of increased CRP (r = 0.4) and IgG RF
(r = 0.4), and significant increase of IgA RF (r = 0.5), anti-
CarP (r = 0.5) levels, but the levels of ESR and IgM RF did
not change significantly (Fig. 3).
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Fig. 2. Associations of RF and Anti-CCP (A), CRP
(B), ESR (C), anti-CarP (D), IgA RF (E), IgM RF
(F), IgG RF (G) levels in RA patients with weakness
and RA patients without fatigue.
Fig. 3. Association strength between different variables measured (VAS,
morning stiffness, DAS28, RF, anti-CCP, ESR, CRP, IgA RF, IgM RF,
IgG RF and CarP antibodies level) in RA patients with fatigue. Col-
our-filled circles in matrix graph represent Spearman’s rank correlation co-
efficients (rs) where size and color of the circles reflect the value of rs, and
more intense colour and bigger size corresponds to higher value of the co-
efficient (see the scale on the right side)..
The level of ESR was positively correlated with the level of
CRP (r = 0.7), while no significant relationship with levels
of IgA RF, IgM RF, IgG RF, and anti-CarP was observed
(Fig. 3).
In RA patients with fatigue, an increase of CRP level did
not result in significant changes of IgA RF, IgM RF, IgG
RF, and anti-CarP levels (Fig. 3).
In the group of RA patients with fatigue, IgA RF level, IgM
RF, IgG RF levels were significantly correlated with anti-
CarP levels (r = 0.8, r = 0.8, and r = 0.6, respectively; Figs.
4, 5). In the cases when IgM RF level increased, also IgG
RF (r = 0.8; Fig. 4) and anti-CarP (r = 0.5; Fig. 5) levels in-
creased significantly (Fig. 3).
In RA patients with fatigue, an increase in IgG RF level was
significantly correlated with increased anti-CarP level (r =
0.5; Figs. 3, 5).
DISCUSSION
Fatigue in RA is highly prevalent and affects at least three-
quarters of patients (Pollard et al., 2006). Fatigue in RA is
multifactorial. There are many different causes of fatigue in
RA patients (Hewlett et al., 2005; Pollard et al., 2006;
Nikolaus et al., 2013; Walsh et al., 2014; Katz, 2017;
Zielinski et al., 2019), which are difficult to interpret in
clinical practice. Previous research has shown that active
RA with inflammation (Madsen et al., 2016) and pain cause
fatigue directly by altered cytokines and also disruption of
sleep due to pain (Nikolaus et al., 2013; Walsh et al., 2014;
Zielinski et al., 2019). Also, persistent pain alters sleep
through changes in mood affecting sleep patterns (Pollard et
al., 2006; Andersson et al., 2013; Katz, 2017; Szady et al.,
2017; Silva et al., 2019; Zielinski et al., 2019). Decreased
physical activity and stress caused by chronic life-changing
RA can also negatively affect energy (Demmelmaier et al.,
2018).
Several studies have shown that RA patients with elevated
immunoglobulin IgA RF and anti-CarP levels have a sig-
nificantly more aggressive clinical course of RA with ero-
sive lesions and radiographic progression (Jonsson et al.,
1998; Shi et al., 2013; Shi et al., 2014; van Delft et al.,
2017; Truchetet et al., 2017) and extra-articular manifesta-
tions (Jonsson et al., 1998). Although the fatigue in RA pa-
tients is being studied, there are quite a few studies about
different RF subtypes and the role of anti-CarP in its devel-
opment. The goal of our study was to evaluate the role of
activity and aggressiveness indices of RA in the severity of
fatigue development in patients who suffer from this dis-
ease.
Based on the results of the survey, the RA patients included
in the study were divided into two groups — with and with-
out fatigue. Changes in arthritis clinical parameters (pain se-
verity, duration of morning stiffness), activity (CRP, ESR,
DAS28(CRP)) and aggressiveness parameters’ (RF, anti-
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Fig. 4. Associations of IgA RF, IgM RF and IgG RF levels (A, B, C) in
RA patients with weakness and RA patients without fatigue.
Fig. 5. Associations of anti-CarP level and IgA RF (A), IgM RF (B), IgG
RF (C) levels in RA patients with weakness and RA patients without fa-
tigue.
CCP, immunoglobulins IgA RF, IgM RF, IgG RF, and
anti-CarP) levels were compared in both groups.
Comparing RA patients with and without fatigue, we found
that in RA patients an increased RF level was significantly
correlated with IgA RF, IgM RF, and IgG RF levels. Sev-
eral studies have shown that RA patients with an increase in
RA levels, especially in IgA RF, develop a more severe dis-
ease than patients without IgA RF (Jonsson et al., 1998).
This suggests that the aggressive course of the disease with
erosion and the development of extracellular damage may
contribute to the development of fatigue in RA patients. Op-
posite results, using a multivariate approach, were found by
Riemsma with colleagues (Riemsma et al., 1998), who
showed that pain explained 37% of the variance in fatigue,
while ESR, RF, and haemoglobin do not contribute to fa-
tigue.
We find that an increase in anti-CCP in RA patients without
fatigue resulted in an increase in IgA RF (r = 0.8) and IgM
RF (r = 0.6) levels, while increase in anti-CCP in RA pa-
tients with fatigue resulted in an increase in IgA RF (r =
0.5) and anti-CarP (r = 0.5) levels. This suggests that high
anti-CCP also tends to influence the development of fa-
tigue, leading to a more aggressive course of the disease in
RA patients with fatigue. Earlier, Cappelli et al. (2015)
found that lower levels of anti-CCP contribute to the devel-
opment of fatigue in RA patients.
Like other authors, we did not find a significant effect of in-
flammation on the development of fatigue in RA patients.
Similarly, also Van Hoogmoed et al. (2010), and Repping-
Wuts et al. (2007) reported that pain, disability, depression,
and low self-efficacy were associated with greater fatigue,
but inflammatory indices were not correlated with fatigue
severity. The fatigue in RA patients may be only partially
related to disease activity, which may have accounted for
poor agreement with respect to a fatigue domain within a
flare questionnaire in RA (Pope, 2020). We found no sig-
nificant difference in pain intensity and morning stiffness
duration between the two study groups. This may be due to
the fact that patients were not observed in dynamics.
In RA patients with fatigue, IgM RF and IgG RF levels in-
creased with an increase of IgA RF level increases, and IgG
RF and anti-CarP levels increased with increase of IgM RF
level, while a higher IgG RF level contributed to increase of
anti-CarP level. No such patter was observed in RA patients
without fatigue. As noted above, the various RF subtypes as
well as anti-CarP, contribute to the development of aggres-
sive erosive arthritis and extracellular damage. The finding
leads to the idea that disease aggressiveness has a role in the
development of fatigue in RA patients. The obtained data
suggest that the aggressive course of RA, more than inflam-
mation, may contribute to the development of fatigue in RA
patients.
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VAI SLIMÎBAS GAITA IETEKMÇ REIMATOÎDÂ ARTRÎTA PACIENTU NOGURUMA ATTÎSTÎBU?
Reimatoîdâ artrîta (RA) pacientiem daudzas locîtavas bieþi ir pastâvîgi iekaisuðas. Ilgstoðs iekaisums organismâ var izraisît vispârçju fizisku
nespçku, spçku izsîkumu un miegainîbu. Ðo ârkârtçja nespçka sajûtu sauc par “nogurumu”. Daïa pacientu uzskata, ka tas ir vissliktâkais
slimîbas simptoms. Tomçr noguruma klîniskâ nozîme un patoìençze nav pilnîbâ skaidra. Ðî pçtîjuma mçríis bija noteikt noguruma attîstîbu
atkarîbâ no RA aktivitâtes un agresivitâtes. Mçría sasniegðanai pacienti tika aptaujâti un tika noteikti laboratoriski slimîbas aktivitâtes un
agresivitâtes râdîtâji: reimatoîdais faktors (RF), antivielas pret ciklisko citrulinçto peptîdu (anti-CCP), eritrocîtu grimðanas âtrums (EGÂ), C
reaktîvais olbaltums (CRO), imûnglobulîni IgA RF, IgM RF, IgG RF un anti-karbamilçto olbaltumvielu antivielas (anti-CarP). Pamatojoties
uz aptaujas rezultâtiem, RA pacienti tika sadalîti divâs grupâs — ar nogurumu un bez tâ. RA pacientu ar nogurumu grupâ statistiski bieþâk
IgA RF, IgM RF un IgG RF lîmeòa paaugstinâðanâs tika novçrota pacientiem ar paaugstinâtu RF lîmeni, augstâks IgM RF un IgG RF
lîmenis bija saistîts ar IgA RF lîmeòa paaugstinâðanos, savukârt palielinâts IgG RF un anti-CarP lîmenis — ar IgM RF lîmeòa
paaugstinâðanos. Augstâks IgG RF lîmenis arî veicinâja anti-CarP lîmeòa paaugstinâðanos. Bûtiskas klînisko un laboratorisko iekaisuma
maríieru lîmeòa atðíirîbas starp RA pacientiem ar noguruma un bez tâ netika novçrotas. Iegûtie dati liecina, ka RA agresîvâ gaita vairâk
nekâ iekaisums var veicinât RA pacientu noguruma attîstîbu.
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